Roche and IBM to Co-Develop, Commercialize IBM's DNA Transistor Technology for Nanopore Sequencing | GenomeWeb

By Monica Heger and Julia Karow

This article was originally published July 1.

Roche and IBM said last week that they will co-develop a nanopore sequencer based on IBM's DNA transistor technology. As part of the agreement, Roche will fund continued development of the technology at IBM and will provide additional resources through its 454 Life Sciences subsidiary. Roche will also receive an exclusive right to market products that are based on the technology.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.